In a post hoc analysis of a phase 2a trial of 98 adults with moderate-to-severe rheumatoid arthritis, the PD-1 agonist peresolimab (700 or 300 mg) lowered PD-1-high CD4 T cells by 52–57% from baseline and neutrophils by >10%, and down-modulated IL-6 and other cytokine pathways.
Secondary analysisn = 98
Benschop et al. Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial